Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + COPL in newly diagnosed advanced NK/T-cell lymphoma
NCT05833893Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in Natural killer T-cell lymphoma (NKTL), sponsored by Chinese PLA General Hospital. Started May 2023; status: recruiting.
02
Drugs
selinexor
03
Conditions
Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT05833893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833893.